Onkure Therapeutics Inc OKUR.OQ OKUR.O is expected to show no change in quarterly revenue when it reports results on November 5 (estimated) for the period ending September 30 2025
LSEG's mean analyst estimate for Onkure Therapeutics Inc is for a loss of $1.20 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Onkure Therapeutics Inc is $32.00, about 89.4% above its last closing price of $3.39
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -1.24 | -1.25 | -1.14 | Beat | 8.7 |
Mar. 31 2025 | -1.46 | -1.46 | -1.19 | Beat | 18.5 |
Dec. 31 2024 | -0.74 | -1.37 | Missed | -85.1 | |
Sep. 30 2024 | -1.03 | -1.03 | -1.10 | Missed | -6.8 |
Jun. 30 2024 | -1.00 | -1.60 | Missed | -60 | |
Mar. 31 2024 | -4.63 | -4.37 | -2.50 | Beat | 42.7 |
Dec. 31 2023 | -5.57 | -5.78 | -7.10 | Missed | -22.9 |
Sep. 30 2023 | -5.66 | -5.71 | -5.70 | Beat | 0.3 |
This summary was machine generated November 3 at 22:40 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)